US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?
Executive Summary
Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.
You may also be interested in...
Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping
Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.
Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping
Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.
FDA Asks For Input On Therapeutic Equivalence
The FDA wants to know if the second letter in its product equivalence ratings system is helpful and whether changes could make the information more user-friendly.